From the IV MB:
>>Fred: Re: We are not alone in our earnings expectation
tp://seekingalpha.com/article/994261-5-biotech-stocks-to-go-long-now?source=yahoo
Excerpt: An upcoming catalyst for BSD is an earnings call scheduled for this Monday, November 12th. The company recently reported significant growth of MicroThermX microwave ablation system sales and equipment utilization. The report notes a 391% increase in sales for the MicroThermX product line for September 2012, as compared to September 2011. Because of this, I think it's likely that the earnings will be a positive surprise to investors.<<
>boraymon ((pleo): AND, on December 6th, BSD M released this statement, note the "586%" specifically for the MTX line and for the Q ending Nov 30th (they ARE trying to keep us up-to-date -- to bad the stock market is so confused:
http://investor.bsdmedical.com/press-release/results-operations-and-corporate-announcements/bsd-medical-reports-significant-quarter
SALT LAKE CITY--( BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 586% increase in sales for the MicroThermX®Microwave Ablation System (MicroThermX®) product line for the fiscal quarter ended November 30, 2012, as compared to the fiscal quarter ended November 30, 2011. Disposable SynchroWave antennas were a significant portion of these sales, reflecting the success of the Company's fee-per-use equipment rental program and increasing sales of MicroThermX® equipment. This is a dramatic increase in sales for MicroThermX® products and representative of a continuing trend of accelerating MicroThermX® revenue.
BSD's current focus is to increase MicroThermX® revenues by expanding the fee-per-use equipment rental program and increasing direct sales support in major U.S. metropolitan areas. These programs continue to produce very successful results, and the current fiscal year promises to provide continuing growth in revenues from the MicroThermX®products. The MicroThermX® introduced into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, providing an important ongoing revenue stream. <
Once again, however, I think they are talking about sales; and they have not, as far as I can tell, issued a statement about how and when they are recognizing the sales revenue (that is Sales). Presumably, they will clarify this soon -- by way of the new CFO. In the meantime, the stock market will likely remain confused -- making this a good time to buy? Make your own decisions, of course; but, I like situations where the stock market appears confused. |
